Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01011478 · ClinicalTrials.gov registry record · Phase 3
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery
A Phase 3 study, sponsored by NSABP Foundation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 406
- Enrollment target
NCT01011478 is a Phase 3 study that was terminated before completion, run by NSABP Foundation. The registered enrollment target is 406 participants.
The verdict
NCT01011478, a Phase 3 study, was terminated before completion, sponsored by NSABP Foundation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 406 participants
- Enrollment target
Study Summary
RATIONALE: Rosuvastatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving rosuvastatin after surgery may kill any tumor cells that remain after surgery. It may also keep polyps from forming or colon cancer from coming back. It is not yet known whether rosuvastatin is more effective than a placebo in treating colon cancer that was removed by surgery. PURPOSE: This randomized phase III trial is studying rosuvastatin to see how well it works compared with placebo in treating patients with stage I or stage II colon cancer that was removed by surgery.
Interventions
- OTHER placebo
- DRUG rosuvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 406 participants |
| Start Date | 2010-03 |
| Est. Completion | 2015-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01011478
The ClinicalTrials.gov registry entry for NCT01011478 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 406 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NSABP Foundation, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01011478 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01011478 about?
NCT01011478 is a clinical study titled "Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery". RATIONALE: Rosuvastatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving rosuvastatin after surgery may kill any tumor cells that remain after surgery. It may also keep polyps from forming or colon cancer from coming back. It is not yet known whether ...
What is the current status of trial NCT01011478?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 406 participants. The study started on 2010-03. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01011478?
The interventions under investigation include: placebo (OTHER), rosuvastatin (DRUG).
Who is sponsoring clinical trial NCT01011478?
This trial is sponsored by NSABP Foundation, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.